Aralez Pharmaceuticals announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.S. rights to Toprol-XL (metoprolol succinate) and its Authorized Generic (AG) from AstraZeneca. In connection with the transaction, the parties entered into a Supply Agreement pursuant to which AstraZeneca will continue to manufacture and supply Toprol-XL and the AG to Aralez Ireland for at least ten years. AstraZeneca will also continue to distribute the product on behalf of Aralez Ireland until the product is transferred, which could be up to nine months following the closing under a transitional services agreement.
Merck & Co. never got its clot-fighting drug Zontivity off the ground. Early estimates of up to $5 billion in sales proved far too optimistic, and last month, the company decided to stop promoting Zontivity in the U.S. altogether.
FDA reviewer backs approval of TMC`s cangrelor
Where Are The ‘Five Stars’ Merck Got From Schering-Plough?
Merck Sharp & Dohme`s Zontivity (Vorapaxar) Approved In Europe For Reducing The Risk of Blood Clots